Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
ROYAL SOC MEDICINE PRESS LTD
Citação
INTERNATIONAL JOURNAL OF STD & AIDS, v.22, n.4, p.209-213, 2011
Resumo
This study was undertaken to evaluate the prevalence of GB virus C (GBV-C) viraemia and anti-E2 antibody, and to assess the effect of co-infection with GBV-C and HIV during a 10-year follow-up of a cohort of 248 HIV-infected women. Laboratory variables (mean and median CD4 counts, and HIV and GBV-C viral loads) and clinical parameters were investigated. At baseline, 115 women had past exposure to GBV-C: 57 (23%) were GBV-C RNA positive and 58 (23%) were anti-E2 positive. There was no statistical difference between the groups (GBV-C RNA + /anti-E2 -, GBV-C RNA - /anti-E2 + and GBV-C RNA - /anti-E2 -) regarding baseline CD4 counts or HIV viral loads (P = 0.360 and 0.713, respectively). Relative risk of death for the GBV-C RNA + /anti-E2 - group was 63% lower than that for the GBV-C RNA - /anti-E2 - group. Multivariate analysis demonstrated that only HIV loads >= 100,000 copies/mL and AIDS-defining illness during follow-up were associated with shorter survival after AIDS development. It is likely that antiretroviral therapy (ART) use in our cohort blurred a putative protective effect related to the presence of GBV-C RNA.
Palavras-chave
GB virus C, prevalence, HIV, co-infection, antiretroviral therapy (ART), hepatitis
Referências
- Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
- Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
- Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
- Tucker TJ, 2000, J MED VIROL, V61, P52, DOI 10.1002/(SICI)1096-9071(200005)61:1<52::AID-JMV8>3.0.CO;2-L
- Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
- Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
- Nunnari G, 2003, ANN INTERN MED, V139, P26
- Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
- Andonov A, 1998, J CLIN MICROBIOL, V36, P286
- Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
- Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1<60::AID-JMV10>3.0.CO;2-A
- DEINHARD.F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673
- GIRET MTM, 2009, AIDS, V23, P1
- Levi José E, 2002, Braz J Infect Dis, V6, P129, DOI 10.1590/S1413-86702002000300005
- Levi Jose Eduardo, 2003, Revista do Instituto de Medicina Tropical de Sao Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
- Linnen JM, 1997, J VIRAL HEPATITIS, V4, P293, DOI 10.1046/j.1365-2893.1997.00064.x
- *MIN SAUD, 2008, B EP
- Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
- Polgreen PM, 2003, MICROBES INFECT, V5, P1255, DOI 10.1016/j.micinf.2003.08.006
- Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
- Sabin CA, 1998, J ACQ IMMUN DEF SYND, V19, P546
- SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
- Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
- Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209